Goff JP, Koszewski NJ, Haynes JS, Horst RL. Targeted delivery of vitamin D to the colon using ␤-glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 302: G460 -G469, 2012. First published November 23, 2011 doi:10.1152/ajpgi.00156.20112D] has been shown to inhibit development of dextran sodium sulfate (DSS)-induced colitis in mice but can also cause hypercalcemia. The aim of this study was to evaluate whether ␤-glucuronides of vitamin D could deliver 1,25(OH)2D to the colon to ameliorate colitis while reducing the risk of hypercalcemia. Initial studies demonstrated that bacteria residing in the lower intestinal tract were capable of liberating 1,25(OH)2D from 1,25-dihydroxyvitamin D3-25-␤-glucuronide [␤-gluc-1,25(OH)2D]. We also determined that a much greater upregulation of the vitamin D-dependent 24-hydroxylase gene (Cyp24) was induced in the colon by treatment of mice with an oral dose of ␤-gluc-1,25(OH)2D than 1,25(OH)2D, demonstrating targeted delivery of 1,25(OH)2D to the colon. We then tested ␤-glucuronides of vitamin D in the mouse DSS colitis model in two studies. In mice receiving DSS dissolved in distilled water and treated with 1,25(OH)2D or ␤-gluc-1,25(OH)2D, severity of colitis was reduced. Combination of ␤-gluc-1,25(OH)2D with 25-hydroxyvitamin D3-25-␤-glucuronide [␤-gluc-25(OH)D] resulted in the greatest reduction of colitis lesions and symptoms in DSS-treated mice. Plasma calcium concentrations were lower in mice treated with ␤-gluc-1,25(OH)2D alone or in combination with ␤-gluc-25(OH)D than in mice treated with 1,25(OH)2D, which were hypercalcemic at the time of death. ␤-Glucuronides of vitamin D compounds can deliver 1,25(OH)2D to the lower intestine and can reduce symptoms and lesions of acute colitis in this model. 1,25-dihydroxyvitamin D 3; 1,25-dihydroxyvitamin D3-25-␤-glucuronide; 24-hydroxylase; dextran sodium sulfate CROHN'S DISEASE AND ULCERATIVE colitis are forms of inflammatory bowel disease (IBD) affecting the lower ileum and colon. IBD, especially Crohn's disease, is often considered an autoimmune disease, characterized by lower intestinal tract innate immune cells that inappropriately secrete proinflammatory cytokines in response to commensal bacteria residing in the lower intestinal tract. Lower intestinal tract Th1 lymphocytes react by secreting IL-2, IL-12, IL-17, TNF-␣, and IFN-␥, inducing excessive inflammation in response to bacterial antigens.
1,25-dihydroxyvitamin D 3; 1,25-dihydroxyvitamin D3-25-␤-glucuronide; 24-hydroxylase; dextran sodium sulfate CROHN'S DISEASE AND ULCERATIVE colitis are forms of inflammatory bowel disease (IBD) affecting the lower ileum and colon. IBD, especially Crohn's disease, is often considered an autoimmune disease, characterized by lower intestinal tract innate immune cells that inappropriately secrete proinflammatory cytokines in response to commensal bacteria residing in the lower intestinal tract. Lower intestinal tract Th1 lymphocytes react by secreting IL-2, IL-12, IL-17, TNF-␣, and IFN-␥, inducing excessive inflammation in response to bacterial antigens.
Epidemiological evidence suggests that geographical location, specifically distance from the equator, is associated with increased incidence of Crohn's disease (17) . One possible explanation for this epidemiological observation is that living closer to the equator increases exposure to the sun's UV-B rays, which may promote cutaneous vitamin D synthesis (21) . In support of this, Ͻ22% of patients recently diagnosed with Crohn's disease had optimal serum 25-hydroxyvitamin D 3 [25(OH)D] levels, defined as Ն75 nmol/l (14) . In a recent clinical trial, treatment of Crohn's patients with vitamin D 3 at 1,200 IU/day caused a small reduction in the risk of relapse (P Ͻ 0.08). Plasma 25(OH)D concentrations were increased from 31 to 96 nmol/l by this treatment (10) .
Since dietary vitamin D absorption is often suboptimal in Crohn's patients, previous work in such patients often focused on the endocrine actions of vitamin D on calcium homeostasis and bone health. The endocrine effects of vitamin D are mediated by renal production of the hormone 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 (2) . Further studies demonstrated that treatment of vitamin D-deficient IL-10 KO mice with 48 pmol (20 ng) of 1,25(OH) 2 D per day reduced expression of TNF-␣, TNF receptor superfamily 1A, and TNF-␣-induced protein 2 in the colon, while reducing or preventing the onset of IBD. Interestingly, this benefit was only observed in mice fed a calcium-sufficient diet (29) . The absence of 1,25(OH) 2 D action on its receptor in lower intestinal cells permits higher numbers of activated dendritic cells to exist in the intestine and may permit autoreactive T cells to develop (5, 27) . Although administration of 1,25(OH) 2 (20) . However, the possibility cannot be ruled out, as we have no assay sensitive enough to detect the glycosidic forms in blood. When administered orally, the ␤-glucuronides of the vitamin D compounds are converted to the active vitamin D moiety upon hydrolysis of the ␤-glucuronide by ␤-glucuronidase produced by bacteria in the lower intestinal tract. This should allow targeted delivery of 1,25(OH) 2 
MATERIALS AND METHODS

General
The ␤-25-monoglucuronides of 1,25(OH)2D and 25(OH)D were synthesized from the corresponding provitamin D or its derivatives using the Koenigs-Knorr reaction (25) . Their structure was confirmed by Fourier transform infrared microscopy and NMR. ␤-Gluc-1,25(OH) 2D (mol wt 592.76) was purified by HPLC to Ͼ97% purity, and ␤-gluc-25(OH)D (mol wt 576.7) was purified by HPLC to Ͼ90% purity; 1,25(OH)2D (mol wt 416.64), 25(OH)D (mol wt 400.6), and 24,25(OH)2D (mol wt 416.64) were Ͼ98% pure (Sigma Aldrich, St. Louis, MO). Quantitation of vitamin D compounds in ethanol solutions utilized to prepare each diet treatment was based on absorbance at 265 nm (using a molar extinction coefficient of 18,300 absorbance units·mol Ϫ1 ·l Ϫ1 ). Male C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were fed Teklad 2018 rodent diet based on wheat, corn, and soybean meal and containing 1% calcium, 0.7% phosphorus, and 1.5 IU of vitamin D 3 per gram (Harlan Labs, Madison, WI). Sprague-Dawley rats (Harlan Labs) were fed Teklad 2018 diet prior to harvest of their intestinal tissue. Animals were housed in individual wire-bottom cages to reduce coprophagy. The room was maintained at 24 -26°C with a 12:12-h light-dark cycle. All procedures performed on the animals were submitted to and approved by the Iowa State University Institutional Animal Care and Use Committee (protocols 4-09-6378-M and 10-08-6651-R).
In Vitro Assessment of ␤-Glucuronidase Activity of Intestine Contents
In most mammals, there are relatively few bacteria in the duodenum, and, generally, bacterial species such as Bacteroides sp. in the lower intestinal tract are capable of cleaving ␤-glycosidic linkages (9) . Rats were chosen to test the ability of the glucuronides of vitamin D to be cleaved in different sections of the intestinal tract. The microbes found in rat intestine are similar to those in mouse intestine, and the amount of intestinal lumen material that could be obtained from the rat intestines allowed for larger incubations of material. The proximal 25 cm of duodenum/jejunum, the caudal 12 cm of ileum, and the cranial 12 cm of colon were removed from 18 Sprague-Dawley rats, and the contents of the lumen from each section were flushed with 3 ml of distilled water, collected, and pooled. Three-milliliter aliquots of intestinal contents were placed into tubes in duplicate. To some tubes, 3.53 pmol of ␤-gluc-1,25(OH) 2D were added, and the contents were incubated at 37°C for 0, 1, 3, or 6 h. To other tubes, 0.36 pmol of 1,25(OH) 2D was added, and the contents were incubated for 0 or 6 h ( Table 1 ). The 1,25(OH)2D-containing tubes served as a control to confirm the ability to extract and detect 1,25(OH)2D in this material and to determine if any degradation of 1,25(OH)2D would occur. added to each tube after incubation to end all enzymatic activity and to extract the 1,25(OH) 2D that was liberated. The preparations were cleaned using a 0.5-g C18OH solid phase extraction column followed by an analytical Zorbax Sil HPLC column (both purchased from Varian, Lexington, MA). ␤-Gluc-1,25(OH)2D, being more watersoluble than 1,25(OH)2D, does not coelute with 1,25(OH)2D on the C18OH or Zorbax Sil column. Samples were analyzed for 1,25(OH)2D content by RIA (Heartland Assays) (8) .
In Vivo Assessment of ␤-Gluc-1,25(OH)2D vs. 1,25(OH)2D on Cyp24 Gene Expression in Colon and Duodenum
Our goal was to determine if ␤-gluc-1,25(OH)2D could be used to target delivery of 1,25(OH)2D activity to the lower intestine. These acute studies allowed us to determine the site of action of a single dose. Two studies were conducted in mice to investigate the relative activity of ␤-gluc-1,25(OH) 2D and 1,25(OH)2D on colon and duodenum, with Cyp24 expression utilized as an indicator of action of the secosteroid on the tissues. Study 1 was a dose-titration study. Tenweek-old ad libitum-fed male C57BL/6 mice received a single oral dose (6, 12, 24 , or 48 pmol) of 1,25(OH) 2D or ␤-gluc-1,25(OH)2D suspended in 50 l of peanut oil (4 mice/treatment). Mice were euthanized 6 h later, blood was collected into heparinized tubes, and the plasma samples were analyzed for 1,25(OH) 2D content by RIA, as described above. Because ␤-gluc-1,25(OH)2D is more water-soluble than 1,25(OH)2D and, therefore, elutes with the methanol wash of the 0.5-g C18OH solid phase extraction column, it is possible to measure only 1,25(OH)2D in the samples.
A 1-cm section of duodenum (2-3 cm from the pylorus) and a 1-cm section of colon (2-3 cm from the cecum) were obtained from each mouse for mRNA analysis. Tissue samples were flushed with ice-cold phosphate-buffered saline and immediately homogenized in 1 ml of TRIzol reagent (Invitrogen, Carlsbad, CA). Samples were kept frozen at Ϫ86°C prior to processing for RNA.
Study 2 was a time-course study. Similarly maintained mice were treated with a single oral 24-pmol dose of 1,25(OH) 2D or ␤-gluc-1,25(OH)2D suspended in 50 l of peanut oil (5 mice/treatment). Mice were euthanized 1, 3, 6, and 24 h after treatment, and plasma and tissues were harvested as described above.
Each TRIzol homogenate was thawed at room temperature, and 500 l were placed in a clean microfuge tube, mixed thoroughly with 100 l of chloroform for 15 s, and then centrifuged at 12,000 g for 15 min at 4°C. The upper aqueous phase was removed and mixed with 0.93 volumes of 75% ethanol. The mixture was applied to an RNeasy spin column (Qiagen, Germantown, MD) and processed as described by the manufacturer, except an additional wash with 2 M NaCl-2 mM EDTA (pH 4.0) was included (3). RNA was eluted in 50 l of water, and the concentration was obtained by UV spectrometry. One microgram of RNA was used as a template for production of cDNA in a 20-l reaction volume using random hexamers and SuperScript III as described by the manufacturer (Invitrogen). The samples were diluted to 100-l final volume with Tris·HCl-EDTA buffer and stored at Ϫ20°C prior to PCR analysis.
Quantitative real-time PCR was performed using a Stratagene Mx3005p cycler (Stratagene, La Jolla, CA) and PerfeCTa SYBR Green FastMix ROX reagent (Quanta Biosciences, Gaithersburg, MD). Amplification of target cDNAs was accomplished with the following primers (synthesized by Integrated DNA Technologies, Coralville, IA): Cyp24 [5=-CACACGCTGGCCTGGGACAC (forward) and 5=-GGAGCTC-CGTGACAGCAGCG (reverse)] and GAPDH [5=-GAAGGTCGGTGT-GAACGGATTTGGC (forward) and 5=-TTGATGTTAGTGGG-GTCTCGCTCCTG (reverse)]. Aliquots (8.3 ng) of cDNA were amplified under the following conditions: 95°C for 30 s, followed by 45 cycles of 95°C for 1 s and 57°C for 30 s. All reactions were performed in duplicate, with four or five animals per treatment, and Cyp24 target gene expression was estimated using the cycle threshold (⌬C T) method relative to GAPDH expression, as described previously (6) .
Testing the Effect of Vitamin D Compounds on DSS-Induced Colitis in Mice
Diet treatments were prepared so that the daily dose of each desired vitamin D compound was delivered in 3.5 g of Teklad 2018 diet. Accordingly, the appropriate amount of each vitamin D compound dissolved in 40 ml of ethanol was thoroughly mixed into the finely ground diet. The diets were left uncovered at room temperature overnight with occasional stirring to allow the ethanol to evaporate. The diets were stored at 4°C between feedings. The dietary treatments began 4 days prior to initiation of colitis with DSS administered in drinking water. The diets were fed at a rate of 3.5 g/day, and any diet not consumed in 24 h was removed and weighed to determine feed refusal (data not shown). Mice were administered 2.5% DSS dissolved in distilled water ad libitum for 7 days. DSS (mol wt 35,000 -50,000) was obtained from MP Biomedicals (Solon, OH). Study 1. Groups of 10-wk-old mice (9 mice/group) were randomly assigned to the different treatments. One group of mice was allowed to drink normal water (No DSS), while all other groups of mice received DSS in their drinking water. Of the groups that received DSS in their drinking water, one group received no vitamin D compounds added to the diet (DSS only). Other groups received treatments consisting of 1,25(OH) 2D incorporated into the diet to supply 24 or 120 pmol/day. ␤-Gluc-1,25(OH) 2D was incorporated into the diet to supply 24, 120, or 600 pmol/day. The final three treatments consisted of ␤-gluc-25(OH)D at 8.67 nmol/day by itself or combined with 24 or 120 pmol of ␤-gluc-1,25(OH) 2D per day. The ␤-gluc-25(OH)D treatment was included to try to competitively inhibit the 24-hydroxylase in the colon and potentiate the effects of 1,25(OH) 2D in the colon. Animals were weighed daily and monitored clinically for bleeding from the rectum and general signs of morbidity. Blood loss from the rectum was scored as follows on the day of necropsy: 0 for no blood, 1 for a single spot of blood in the cage, 2 for Ͻ10 spots of blood in the cage, and 3 for Ͼ10 spots of blood in the cage. One mouse in the treatment group receiving 600 pmol of ␤-gluc-1,25(OH) 2D per day in study 1 failed to finish the trial, as it developed severe bloody diarrhea and weight loss, necessitating euthanasia on day 7 of DSS administration. Its tissues were collected, and data from this mouse are retained in the study results. After 7 days of consuming DSS in their drinking water, the mice were offered regular tap water for 24 h and euthanized by guillotine while under isoflurane anesthesia.
Blood was collected from the cervical stump into heparinized tubes, and each mouse's plasma was harvested and frozen at Ϫ86°C until it was analyzed for calcium content by a colorimetric assay (Arsenazo III, Pointe Scientific, Canton, MI). Plasma 25(OH)D and 1,25(OH) 2D concentrations were determined by RIA on pooled samples of plasma collected from the mice (Heartland Assays) (7, 8) . In study 1, each pooled sample consisted of 50 l of plasma from four or five mice, resulting in two samples per treatment. In study 2, each pooled sample consisted of 100 l of plasma from three mice, resulting in three samples per treatment. Because of the small number of samples, the results of the vitamin D metabolite determinations were not subjected to statistical analysis.
The entire colon and rectum of each mouse was removed intact, and the length was recorded. The colon/rectum was cut in half, and the caudal half was discarded. The caudal 1 cm of the remaining half was fixed in formalin for histopathological analysis. The fixed colon section was stained with hematoxylin-eosin for microscopic histopathological evaluation by a veterinary pathologist (J. S. Haynes) blinded to the treatments. Each tissue section received a score of 0 -4, from no lesion to severe extensive lesion, for each of three criteria: 1) the degree of erosion/ulceration of colon mucosa, 2) the degree of infiltration of the tissues by inflammatory cells, and 3) the degree of submucosal edema. The sum of the score of each of these criteria constitutes the histopathological score for the tissue, with a 0 score representing normal tissue based on all criteria and the worst possible outcome being a score of 12.
A second 1-cm piece of colon tissue cranial to the section used for histopathological analysis was obtained from each mouse for isolation of mRNA. In study 1, the tissues were flash-frozen. Unfortunately, the RNA isolated from these tissues was degraded. In study 2, the tissues were immediately placed into TRIzol and homogenized as described above for the dose and time-course studies on effects of a single dose of the vitamin D compounds. This method successfully preserved the RNA. Quantitative real-time PCR was performed and quantitated as described above. Amplification of target cDNAs for Cyp24, TNF-␣, and cadherin 1 was accomplished with the following primers: TNF-␣ [5=-AGGGGCCAC-CACGCTCTTCT (forward) and 5=-CCACTCCAGCTGCTCCTC-CACT (reverse)] and cadherin 1 [5=-TGGAGGGATCCTCGCCCTGC (forward) and 5=-CATCCAGGCCCCTGTGCAGC (reverse)].
Statistical Analysis
Data were analyzed by one-way ANOVA (SAS, Cary, NC). When ANOVA suggested a significant difference (P Ͻ 0.05), post hoc comparison of individual means was conducted using Fisher's test of least significant difference. Results from studies of the mice treated with DSS to induce inflammation of the lower bowel are presented as treatment differences from the positive (No DSS) or negative (DSS only) control means and are considered significant at P Ͻ 0.05, unless otherwise noted. Results of several of the treatments from study 1 with no significant effects are not presented in Tables 2 and 3 to improve clarity of presentation, but any significant effects attributable to these treatments are discussed in the text.
RESULTS
Ileal and Colon, but not Duodenal, Contents Have High Levels of ␤-Glucuronidase Activity
To determine the ␤-glucuronidase activity capable of liberating a vitamin D aglycone from the prodrug form of the vitamin D compound in various parts of the small intestine, ␤-glucuronidase activity was tested in contents from intestinal subsections of rats. The assay system recovered Ն60% of the added 1,25(OH) 2 (Fig. 2C ). Higher doses of either compound resulted in higher levels of 1,25(OH) 2 D in the blood. At the 48-pmol dose, ␤-gluc-1,25(OH) 2 D resulted in higher blood 1,25(OH) 2 D at the time of euthanasia, which was 6 h after treatment in this study. Plasma calcium concentrations were similar to control mouse plasma calcium concentrations in all treatment groups, which likely reflects the short duration of the experiment.
When 24 pmol of ␤-gluc-1,25(OH) 2 D or 1,25(OH) 2 D were administered orally and the animals were killed at intervals following treatment, the highest levels of expression of Cyp24 in the colon and duodenum were observed 3 or 6 h after treatment (Fig. 3, A and B) . In colon tissue, ␤-gluc-1,25(OH) 2 D treatment caused a ϳ700-fold increase in Cyp24 expression compared with control mice at 6 h, whereas 1,25(OH) 2 D caused only a ϳ5-fold increase. In the duodenum, the relative effects of 1,25(OH) 2 D and ␤-gluc-1,25(OH) 2 D were reversed. Compared with control mice, 1,25(OH) 2 D treatment steadily increased Cyp24 expression in the duodenum from 1 h (350-fold induction) to 3 h (1,600-fold induction) to 6 h (Ͼ2,500-fold). In contrast, the effects of ␤-gluc-1,25(OH) 2 D on Cyp24 expression peaked at 3 h in the duodenum, with a 1,300-fold increase, and fell to a 500-fold increase at 6 h. The effects of 1,25(OH) 2 D and ␤-gluc-1,25(OH) 2 D on Cyp24 gene expression in both tissues was similar to control mouse levels 24 h after treatment.
Plasma concentrations of 1,25(OH) 2 D peaked at 1 h following oral treatment with 24 pmol at 1,280 pg/ml, a ϳ14-fold increase over control mouse plasma 1,25(OH) 2 D (Fig. 3C) . In contrast, the average plasma 1,25(OH) 2 D concentration in mice treated with 24 pmol of ␤-gluc-1,25(OH) 2 D peaked ϳ3 h after treatment at 325 pg/ml, a level that was only 3.5-fold greater than control levels. By 24 h after treatment, plasma 1,25(OH) 2 However, the time at which each drug causes peak levels of 1,25(OH) 2 D in the blood differs. As expected, the highest plasma concentrations of 1,25(OH) 2 D occur shortly after oral administration of 1,25(OH) 2 D, and concentrations decline thereafter due to rapid metabolism of 1,25(OH) 2 D in the mouse. However, there is a delay in the time to peak 1,25(OH) 2 D concentrations in mice receiving ␤-gluc-1,25(OH) 2 D. This likely represents the amount of time required for the compound to reach the ileum and to be converted to 1,25(OH) 2 D and then to be absorbed into the circulation. Quantitative real-time PCR was also used to examine changes in expression of the VDR and calbindin-D9k, both of which are commonly reported to be upregulated by 1,25(OH) 2 D. We could not detect changes in expression of these genes in these tissues (data not shown). These animals were vitamin D-replete; most studies demonstrating strong upregulation of these proteins are done using vitamin D-deficient animals. Our studies were completed Ͻ24 h after treatment. Many of the studies demonstrating a VDR or calbindin-D9k response require repeated doses of 1,25(OH) 2 D over Ͼ24 h to see significant upregulation in the animal's tissues. Also, when VDR expression is upregulated, it may be just a three-to fourfold increase (23) .
Effect of Vitamin D Compounds on DSS-Induced Colitis
Study 1. Control mice that did not receive DSS gained 1.91 g body wt during the 8 days of the IBD induction period and had no blood in their feces, and their colon length was 6.89 Ϯ 0.37 cm. Their plasma calcium was 9.54 Ϯ 0.11 mg/dl. In the mice treated with DSS alone, frank blood began to appear in the feces ϳ6 days after the start of addition of DSS to their drinking water, and at the time of death these animals had an average fecal blood score of 0.89 Ϯ 0.34 and colon length of 5.22 Ϯ 0.20 cm and had lost 1.03 g body wt (4.7% of initial body weight) during the 8 days following the start of addition of DSS to their drinking water (Tables 2 and 3 ). Their histopathology colon lesion score was 9.33 Ϯ 0.62. The DSStreated mice were significantly hypocalcemic at the time of death, with plasma calcium of 8.44 Ϯ 0.36 mg/dl. Severe inflammatory processes often result in high levels of IL-1 and other cytokines, which cause a decline in blood calcium level via mechanisms that may involve vitamin D, parathyroid hormone, or calcitonin (19, 28) .
Mice receiving DSS in their drinking water and treated with 1,25(OH) 2 D or ␤-gluc-1,25(OH) 2 D at 120 pmol/day had reduced fecal blood scores and reduced colon lesion scores. Colon length and weight loss in both groups were not statisti- Values are means Ϯ SE; n ϭ 9 mice per treatment. IBD, inflammatory bowel disease. Mice received diets containing treatments that included 1,25(OH)2D, ␤-gluc-1,25(OH)2D, and 25-hydroxyvitamin D3-25-␤-glucuronide [␤-gluc-25(OH)D]. Diet treatments began 4 days prior to initiation of dextran sodium sulfate (DSS)-water and continued until the animals were euthanized. DSS-water was administered for 7 days, and mice were euthanized on day 8. Fecal blood was scored on a scale of 0 -3, where 0 ϭ no blood and 3 ϭ multiple blood spots in the cage. Colon lesions were scored on a scale of 0 -12, where 0 ϭ no lesions and 12 ϭ severe erosion, hemorrhage, and submucosal edema. Change in body weight ϭ body weight on day 8 of DSS period Ϫ average body weight over the 3 days prior to initiation of DSS treatment. *Significantly different from DSS only (P Ͻ 0.05). †Significantly different from No DSS (P Ͻ 0.05). Values are means Ϯ SE; n ϭ 9 mice per treatment. Mice received diets containing treatments that included 1,25(OH)2D, ␤-gluc-1,25(OH)2D, and ␤-gluc-25(OH)D. Diet treatments began 4 days prior to initiation of DSS-water and continued until the animals were euthanized. DSS-water was administered for 7 days, and mice were euthanized on day 8. rent treatment with 8.67 nmol/day of ␤-gluc-25(OH)D, fared somewhat better. Their colon lesion scores were significantly lower and they lost less weight than mice treated with DSS alone, but colon length and fecal blood score were not improved (data not included in Tables 2 and 3 Study 2. All mice completed study 2, and the degree of colitis, based on body weight loss, histopathological colon lesion score, and colon length, experienced by the DSS-only group was milder than in the mice that completed study 1. Compared with mice not receiving DSS in their drinking water, DSS-only mice had significantly more blood in their feces, shorter colon length, and lost more body weight (Table 4) . Fecal blood score was 1.33 Ϯ 0.49 in DSS-only mice. The treatment consisting of 171 pmol of ␤-gluc-1,25(OH) 2 D per day (a 42% increase in the dose found to be effective in study 1) significantly reduced fecal blood score (0.33 Ϯ 0.33, P Ͻ 0.05) and body weight loss (P Ͻ 0.075) compared with DSS-only mice. In addition, colon length of the mice receiving 171 pmol of ␤-gluc-1,25(OH) 2 D per day (7.40 Ϯ 0.22 cm) was not statistically different from that of No-DSS control mice (7.57 Ϯ 0.34 cm) and was statistically improved compared with DSS-only mice (6.68 Ϯ 0.19 cm, P Ͻ 0.075). Plasma calcium of DSS-only mice was lower than that of no-DSS mice (P Ͻ 0.075), but none of the vitamin D treatments caused a significant increase in plasma calcium concentration (P Ͼ 0.075; Table 5 ). Histopathology colon lesion score for the DSS-only mice was much lower than in study 1 (3.67 vs. 9.33 in study 2) , indicating that a milder inflammation was induced by DSS in this trial. Treatment with 171 pmol of ␤-gluc-1,25(OH) 2 D per day did not alter colon lesion score, although fecal blood score and colon length were improved over DSSonly mice.
Plasma 25(OH)D concentrations were decreased in animals receiving DSS in their drinking water, similar to the animals receiving DSS in study 1. . Diet treatments began 4 days prior to initiation of DSS-water and continued until the animals were euthanized. DSS-water was administered for 7 days, and mice were euthanized on day 8. Body weight change, fecal blood score, and histopathology colon lesion score are described in Table 2 footnote. *Significantly different from No DSS (P Ͻ 0.05). †Significantly different from DSS only (P Ͻ 0.075). Values are means Ϯ SE; n ϭ 6 mice per treatment. Mice received diets containing treatments that included carrier or 171 pmol of ␤-gluc-1,25(OH)2D. Diet treatments began 4 days prior to initiation of DSS-water and continued until the animals were euthanized. DSS-water was administered for 7 days, and mice were euthanized on day 8. aglycone vitamin D compound. As these studies demonstrate, glucuronidase activity in the upper small intestine is unlikely to allow formation of significant amounts of the aglycone vitamin D compounds. However, the colon and ileum possess substantial numbers of bacteria, which are able to produce ␤-glucuronidase, and nearly all the glucuronide is cleaved from the vitamin D compounds very rapidly. Administration of a single oral dose of 24 pmol of 1,25(OH) 2 D had a profound impact on duodenal Cyp24 expression that persisted for Ն6 h but was essentially gone by 24 h. The colon responded to oral administration of 24 pmol of 1,25(OH) 2 D with a fivefold increase in colon Cyp24 expression. In contrast, the equimolar amount of ␤-gluc-1,25(OH) 2 D administered orally was much less able to upregulate duodenal Cyp24 expression than 1,25(OH) 2 D. ␤-Gluc-1,25(OH) 2 D was able to upregulate colon Cyp24 expression ϳ700-fold by 6 h after treatment, Ͼ100 times as active on colon tissues as the native hormone. Daily feeding of 24 pmol of ␤-gluc-1,25(OH) 2 D improved a few aspects of IBD in the DSS-treated mice, but this effect was modest at best. Feeding five or seven times this amount of ␤-gluc-1,25(OH) 2 D (120 or 171 pmol/day) resulted in a modest improvement in lesions of IBD compared with the lower dose. A ␤-gluc-1,25(OH) 2 D dose of 600 pmol/day proved to be toxic: it was associated with hypercalcemia (10.72 mg Ca/dl), and the mice consumed less diet, lost more body weight than animals subjected to the other treatments, and had IBD that was nearly identical to the animals receiving DSS only. Although it is less hypercalcemic than the native hormone 1,25(OH) 2 2 D, causes T cell differentiation to shift from Th1-and Th17-predominant phenotypes toward a Th2 phenotype (1) and downregulates gut-homing receptors expressed by T cells that migrate selectively to the intestinal tract (26) . In support of this, vitamin D deficiency exacerbates symptoms of colitis in IL-10 KO mice (2) , and VDR knockout mice are ultrasensitive to DSS-induced IBD (5) . Some Crohn's patients are known to have a genetic variant of the NOD2 gene, which is a pattern recognition receptor that recognizes bacterial peptidoglycans. It appears that the innate immune cells, such as monocytes and macrophages, of these patients fail to recognize certain bacterial cell wall antigens, Fig. 4 . Colon expression of Cyp24, TNF-␣, and cadherin 1 (Cadh1) in mice from study 2. Control mice received no dextran sodium sulfate (DSS) in their drinking water, and DSS mice received 2.5% DSS their drinking water for 7 days. DSS ϩ ␤-gluc-1,25(OH)2D mice received DSS in their drinking water and 171 pmol of ␤-gluc-1,25(OH)2D mixed with their diet each day. Mice were killed 8 days after initiation of DSS to their drinking water.
and thus the cells are unable to initiate a cascade of events leading to production of antimicrobial peptides that might keep "inflammation-triggering" bacteria populations in check. NOD2 and Toll-like receptor pathways also stimulate the innate immune cell's ability to perform 1␣-hydroxylation of 25(OH)D (16 (16) . Cathelicidin's ability to kill Mycobacteria may be critical to preventing IBD, especially if a major factor precipitating IBD proves to be the presence of Mycobacterium avium sp. paratuberculosis in the gut. Finally, the intestinal epithelial barrier, consisting of epithelial cells and intercellular tight junctions, prevents microorganisms, toxins, and luminal antigens from entering the body. Impaired barrier function is a common finding in patients with IBD (4) . Studies in mice demonstrate that 1,25(OH) 2 D acts on enterocytes to increase expression of junction proteins to maintain the integrity of the intestinal mucosal barrier and allow rapid repair of damage to enterocyte tight junctions, which may facilitate recovery from a bout of IBD (11) . In our study, there appeared to be some loss of cadherin 1 as a result of DSS treatment, but this was not statistically significant, and, more importantly, we could not demonstrate an increase in cadherin 1 expression following treatment with ␤-gluc-1,25(OH) 2 D.
Utilizing ␤-glucuronide forms of 1,25(OH) 2 D and 25(OH)D allows delivery of 1,25(OH) 2 D and 25(OH)D to the colon in amounts that stimulate colon gene expression to a much higher degree than is possible with the native hormone, 1,25(OH) 2 D. These compounds, at the doses that proved effective in this mouse model, also avoid the development of severe hypercalcemia observed with native 1,25(OH) 2 D. In this mouse model of IBD, the amelioration of IBD provided by ␤-gluc-1,25(OH) 2 D ϩ ␤-gluc-25(OH)D was superior to that achieved with ␤-gluc-1,25(OH) 2 D alone. We believe that this is due to competitive inhibition of the 24-hydroxylase enzyme, prolonging the action of 1,25(OH) 2 D within the colon. It is also possible that provision of high amounts of 25(OH)D to the colon may also provide sufficient substrate to drive colon 1␣-hydroxylase and enhance 1,25(OH) 2 D production within the epithelial and immune cells of the colon.
